Pioglitazone vs glimepiride in the PERISCOPE trial.
Shah
Rahman
R
D050197:Atherosclerosis / Q000209:etiology / Q000517:prevention & control; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000077205:Pioglitazone; D012306:Risk; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D045162:Thiazolidinediones / Q000627:therapeutic use*; D018084:Ultrasonography, Interventional
D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; C057619:glimepiride; D000077205:Pioglitazone